BACKGROUND Antiarrhythmic drugs are widely used to treat patients with atrial fibrillation (AF), but the mechanisms
A trial fibrillation (AF) causes cardiovascular death, frequent hospitalization, and cognitive decline even in patients treated according to guidelines (1-3). Antiarrhythmic drug (AAD) therapy remains the most commonly used treatment to maintain sinus rhythm in AF patients, but AAD effectiveness remains limited (3). Unfortunately, we lack a basic understanding of why AADs prevent AF over long periods in some patients but not in others (4, 5) . Identifying factors that modify the effects of AADs would allow the selection of responsive patients and could help guide development of novel AADs (6) .
Paired like homeodomain-2 transcription factor (PITX2) is a transcription factor that regulates the development of the left atrium (LA) and thoracic organs. Its c isoform is expressed in the adult LA and regulates the expression of LA ion channels (7) (8) (9) . Low atrial Pitx2 expression renders mice susceptible to AF and shortens the LA action potential (8, 10, 11) . In this study, we investigated how atrial PITX2 modifies the effects of AADs.
We detected variable LA PITX2 messenger ribonucleic acid (mRNA) expression in AF patients requiring rhythm control therapy. After finding that low Pitx2c enhanced the effect of flecainide, mediated by a more positive resting membrane potential (RMP), we identified reduced TWIK-related acid-sensitive K þ channel 2 (TASK-2) expression as a possible driver of this effect and replicated these effects in cells expressing human sodium (Na) channels and in a human atrial action potential model.
METHODS
All experiments were conducted under the Animals Single nucleotide polymorphisms (SNPs) rs2200733, rs6838973, and rs1448818 (14) were identified using TaqMan assays (Thermo Fisher Scientific Inc., Waltham, Massachusetts).
Adult mice (age 12 to 16 weeks) on an MF1 background with normal or reduced (Pitx2c þ/À ) atrial Pitx2c expression were studied (8) .
LA epicardial monophasic action potentials were recorded from Langendorff-perfused murine hearts (8, 15) . Programmed stimulation was performed at baseline and with flecainide 1 mmol/l or d,l-sotalol 10 mmol/l. Arrhythmia inducibility and effective refractory period (ERP) were measured by using single right atrial extrastimuli after steady-state pacing in 1-ms decrements (15) (16) (17) (18) . Transmembrane action potentials were recorded using borosilicate glass microelectrodes from superfused murine LAs (17), RMP, action potential duration (APD), upstroke velocity, and activation times were analyzed (15, 17, 18) .
The human atrial cell model of Courtemanche et al. Syeda et al.
refractoriness (PRR) was calculated as the difference between APD at -60 mV repolarization and ERP.
LA cell isolation was performed as previously reported (20) . Standard I Na and I K1 currents were recorded as previously published (18) (19) (20) Values are mean AE SD (range), n, or mean (range). *Left atrial appendages were collected from these patients with atrial fibrillation (AF).
PVI ¼ pulmonary vein isolation. Syeda et al. Tables 1 and 2 . Values are mean AE SEM (number of atria). Tables 2 and 3 . Pitx2c expression ( Figures 1D and 1E , Table 3 ). Syeda et al. Because the Courtemanche-Ramirez-Nattel model does not incorporate background K þ currents (19), we simulated a depolarized RMP in this model by a 25% reduction in I K1 . This reduced the RMP at 500-ms paced cycle length by 2 mV from 79.9 mV ("normal PITX2") to -77.9 mV ("low PITX2"). Na channels recovered from inactivation more slowly upon partial I Na block (50% or 60%) ( Figure 3A) . Furthermore, PRR was enhanced in the PITX2 deficiency model ( Figure 3B and Table 5 ). Inhibition of I Na reduced upstroke velocity (dV/dt max ) and conduction velocity in both models, and reproduced the prolongation of PRR ( Figure 3B ).
Abbreviations as in
Kcna6 and Kcnk5 mRNA expression were reduced in ( Figures 5D and 5E ).
Background K þ currents, which include TASK currents, were reduced in Pitx2c þ/-murine atria, whereas I K1 did not differ between genotypes ( Figure 6 ). Figures 1E and 1F) . Additionally, expression of the Na/Ca exchanger Serca2a
and Na/K ATPase alpha-1 and alpha-2 subunit protein did not differ between wild-type and Pitx2c Syeda et al. confirmed that small changes in RMP can markedly modulate Na-channel inhibition.
RESTING MEMBRANE POTENTIAL. Open-state Nachannel blockers such as flecainide and propafenone bind preferentially to Na channels integrated in membranes with slightly depolarized resting potentials, where more channels are in the open or inactivated state (31, 32) . Our data can be interpreted as suggesting that AAD combinations that include a Nachannel blocker with a membrane potential modifying substance, such as amiodarone (16, 33) or the combination of dronedarone and ranolazine (29, 34, 35) , may have synergistic antiarrhythmic effects because they modulate atrial RMP and thereby enhance the effect of Na-channel blockade. Further studies of such drug combinations and the relationship between their effectiveness and the patient's atrial PITX2 mRNA levels are warranted. Our data also suggested that such combined effects may be of special relevance in patients who have a depolarized RMP, such as secondary to low LA PITX2. Because PITX2 expression is confined to the LA in the heart, AAD therapy that leverages modifications in RMP may achieve "atrial-specific" AAD therapy.
RMP is maintained by an intricate balance of different transmembrane currents and is closely related to the potassium equilibrium potential. We identified that PITX2 modifies expression of the genes encoding K v 1.6 and TASK-2 ( Figure 4) . Complete deletion of PITX2 regulates other potassium and Na channels such as Kcnj2 (8, 36) , which alter the RMP, but these were not responsible for the depolarized RMP observed in our study. Two-pore domain potassium channels, such as TASK-2, contribute to RMP in various cells, including skeletal and cardiac muscle (37, 38) . To date, an altered function of the TASK-1 channel and of I K1 has been implicated in atrial remodeling and AF (39, 40) . This study demonstrated that TASK-2 is expressed in atrial myocardium ( Figure 4B ), suggesting that a reduced function of TASK-2 could depolarize RMP (Figures 1 and 5) (8,11) , analogous to the effect of TASK-2 in neuronal and cartilage tissue (41, 42) .
DEVELOPING CLINICAL MARKERS FOR PATIENTS
WITH DEPOLARIZED RMP. It will be challenging to directly assess LA RMP in AF patients, but our data suggested that differences in atrial RMP could explain the effectiveness of Na-channel blockers in carriers of an assumption that has not been definitively proven (9, 11, 44, 46) . Our analysis ( 
chromosome 4q25 proves elusive. The mechanisms by which reduced PITX2 mRNA concentrations shorten the LA action potential at high heart rates remain to be fully elucidated (8, 20) . Validating our findings in patients is desirable but will be challenging because access to fresh LA cardiomyocytes and LA tissue is limited.
Due to the novelty of our findings, we could not perform a priori power calculations for our mechanistic experiments, and we analyzed several functional parameters to identify potential mechanisms conveying the antiarrhythmic effects of flecainide in atria with low Pitx2c concentrations. Our findings thus require independent validation. Values are mean AE SEM (number of atria).
-¼ not applicable; other abbreviations as in Table 3 . Syeda et al.
